OptiNose, Inc. (NASDAQ:OPTN) will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.optinose.com
Earnings Expectation
OptiNose, Inc. is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.52 per share from $ 14.28 million in revenue. For the full year, analysts predict revenues of $ 50.68 million, while looking forward to loss of $ 2.16 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 15.40 million ~ $ 15.40 million
Click Here For More Historical Outlooks Of OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.
